Related Experiment Video
Updated: May 26, 2026

A Machine Learning Approach to Design an Efficient Selective Screening of Mild Cognitive Impairment
Published on: January 11, 2020
The neuropathological profile of mild cognitive impairment (MCI): a systematic review
B C M Stephan1, S Hunter, D Harris
1Department of Public Health and Primary Care, Institute of Public Health, Cambridge University, Cambridge, UK. bcms2@cam.ac.uk
Abstract:
Whether mild cognitive impairment (MCI) has a distinct neuropathological profile that reflects an intermediate state between no cognitive impairment and dementia is not clear. Identifying which biological events occur at the earliest stage of progressive disease and which are secondary to the neuropathological process is important for understating pathological pathways and for targeted disease prevention. Many studies have now reported on the neurobiology of this intermediate stage. In this systematic review, we synthesize current evidence on the neuropathological profile of MCI. A total of 162 studies were identified with varied definition of MCI, settings ranging from population to specialist clinics and a wide range of objectives. From these studies, it is clear that MCI is neuropathologically complex and cannot be understood within a single framework. Pathological changes identified include plaque and tangle formation, vascular pathologies, neurochemical deficits, cellular injury, inflammation, oxidative stress, mitochondrial changes, changes in genomic activity, synaptic dysfunction, disturbed protein metabolism and disrupted metabolic homeostasis. Determining which factors primarily drive neurodegeneration and dementia and which are secondary features of disease progression still requires further research. Standardization of the definition of MCI and reporting of pathology would greatly assist in building an integrated picture of the clinical and neuropathological profile of MCI.
Insights
Mild cognitive impairment (MCI) presents a complex neuropathological profile, not fitting a single framework. Further research is needed to distinguish primary drivers of neurodegeneration from secondary disease progression features.
Area of Science:
- Neurology
- Neuroscience
- Pathology
Background:
- Mild cognitive impairment (MCI) is an intermediate stage between normal cognition and dementia.
- Understanding MCI's neuropathology is crucial for identifying early disease events and preventing progression.
- Current evidence on MCI's neurobiology is extensive but requires synthesis.
Purpose of the Study:
- To systematically review and synthesize current evidence on the neuropathological profile of mild cognitive impairment (MCI).
- To clarify whether MCI has a distinct neuropathological profile indicative of an intermediate stage of neurodegeneration.
Main Methods:
- Systematic review of 162 studies.
- Analysis of studies with varied MCI definitions, settings, and objectives.
- Synthesis of reported neuropathological findings in MCI.
Main Results:
- Mild cognitive impairment (MCI) is neuropathologically complex and cannot be explained by a single model.
- Identified pathologies include amyloid plaques, neurofibrillary tangles, vascular issues, inflammation, oxidative stress, and metabolic disturbances.
- The review highlights the need to differentiate primary neurodegenerative drivers from secondary changes.
Conclusions:
- Mild cognitive impairment (MCI) exhibits a multifaceted neuropathology.
- Further research is essential to determine primary versus secondary pathological mechanisms in MCI progression.
- Standardizing MCI definitions and pathology reporting is recommended for a clearer understanding.
More Related Videos
06:23The 4 Mountains Test: A Short Test of Spatial Memory with High Sensitivity for the Diagnosis of Pre-dementia Alzheimer's Disease
Published on: October 13, 2016
08:29Symmetric Bihemispheric Postmortem Brain Cutting to Study Healthy and Pathological Brain Conditions in Humans
Published on: December 18, 2016
Related Concept Videos
Alzheimer's Disease: Overview
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
Dementia l: Introduction
Alzheimer Disease ll: Pathophysiology
Alzheimer Disease l: Introduction
Dementia
The progression of dementia is generally gradual.
Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists